Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2/PHASE3
69 participants
INTERVENTIONAL
2009-01-31
2012-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Kineret® is already being used in the treatment of patients suffering from rheumatoid arthritis and preclinical studies are now suggesting that it may also be useful for patients with Type 1 diabetes. The active substance in Kineret is interleukin-1 receptor antagonist, a blocker of an immune-signal molecule named interleukin-1.
The trial is a blinded randomised trial, in which the patient is allocated to receive the active drug (Kineret®) or placebo (saline). The hypothesis is that anti-IL-1 treatment as add-on therapy to conventional insulin therapy will preserve or enhance beta-cell function.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The aim of the Anti-Interleukin-1 in Diabetes Action trial (AIDA) study is to test the feasibility, safety/tolerability and potential efficacy of anti-IL-1 therapy in maintaining or enhancing beta-cell function in people with new onset Type 1 diabetes.
Trial Design:
A randomized, placebo controlled, double masked, parallel group, multicentre trial of IL-1 antagonism in subjects with newly-diagnosed Type 1 diabetes. Patients are instructed to inject 100 mg human recombinant interleukin-1 receptor antagonist (anakinra, Kineret®, Amgen, CA) or placebo s.c. once daily for 2 years. Endpoints will be evaluated every three months, with an interim analysis after 6 months.
Trial population:
The design will be a two-stage phase 2a study to address feasibility, safety/tolerability and potential efficacy. In the first phase 80 patients between 18 and 35 years of age with new on-set Type 1 diabetes will be randomized to anakinra or placebo, and endpoints will be analyzed as an interim analysis after 6 months by an independent data and safety monitoring board (DSMB). A futility analysis will be performed at this time point to prevent continuation of the trial if it shows no likelihood of demonstrating efficacy. In the event the trial does show promise of efficacy considering the power of the first phase based on a conditional analysis the DSMB can recommend prolongation of the study with recruitment to ensure adequate power, and that additional funding is provided.
Methods and interventions:
The patients are instructed to administer anti-IL-1 therapy in the form of recombinant human non-glycosylated interleukin-1 receptor antagonist (anakinra) at a dose of 100 mg once daily or placebo by subcutaneous injection at the same time-point in the morning. Primary and secondary endpoints and safety parameters are investigated after 1 month and then every 3 months.
Safety:
Anakinra is FDA approved for the indication rheumatoid arthritis and has an acceptable risk / benefit profile in this indication, with more than 100.000 patients treated. Most common ad-verse events include mild and transient local injection reactions in 20-50% of subjects treated with Anakinra. Consistent with its mechanism of action, anakinra reduces WBC/ANC in 2.4% of patients and this may increase the risk of infection. Accordingly, treatment with anakinra will not be initiated in patients with active infections. Safety will be monitored by physical exams and blood and urine tests.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
2
The patients are instructed to administer placebo by subcutaneous injection
saline
The patients are instructed to administer placebo (saline) once daily by subcutaneous injection
1
The patients are instructed to administer anti-IL-1 therapy in the form of recombinant human non-glycosylated interleukin-1 receptor antagonist (IL-1Ra, anakinra, Kineret®, Amgen, CA, USA) \[13\] at a dose of 100 mg once daily by subcutaneous injection
anakinra
The patients are instructed to administer anti-IL-1 therapy in the form of recombinant human non-glycosylated interleukin-1 receptor antagonist (IL-1Ra, anakinra, Kineret®, Amgen, CA, USA) \[13\] at a dose of 100 mg once daily by subcutaneous injection
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
anakinra
The patients are instructed to administer anti-IL-1 therapy in the form of recombinant human non-glycosylated interleukin-1 receptor antagonist (IL-1Ra, anakinra, Kineret®, Amgen, CA, USA) \[13\] at a dose of 100 mg once daily by subcutaneous injection
saline
The patients are instructed to administer placebo (saline) once daily by subcutaneous injection
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Positive GAD auto-antibodies
* Age 18-35 yrs at onset of diabetes
* Time from first symptoms of diabetes \< 12 weeks
* Peak C-peptide more than or equal to 200 pM after a standardized mixed meal test (Boost) at a test carried out when the subject is metabolically stable, i.e. after resolution of any polyuria, polydypsia or ketoacidosis.
Exclusion Criteria
* History of heart disease, signs of cardiac failure or abnormal ECG
* Present or previous malignancy
* Pregnancy or failure of fertile female to comply with contraceptional planning, or breast-feeding. (Safe contraceptive methods include birth control pills, IUD, and gestagen implants) . Plans of pregnancy within 2 years.
* Participation in other clinical intervention studies
* Anti-inflammatory therapy (except aspirin £ 100 mg/d)
* Active infections (CRP\>30), history of recurrent infection or predisposition to infections
* Neutropenia: ANC \< 1.5\*109/L, or anaemia: Haemoglobin \< 8.0 g/dL
* Immune-suppressive treatment or immune-deficiency
* Presence at diagnosis of late diabetic complications
* Concurrent vaccination with live vaccine. Known need for live vaccinations within 2 years.
* Use of Etanercept within 6 months before screening or during the double-blinded study period
* Hypersensitivity to E. coli-derived proteins, anakinra or any components of the product.
18 Years
35 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Juvenile Diabetes Research Foundation
OTHER
Oeresund Diabetes Academy
UNKNOWN
Steno Diabetes Center Copenhagen
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Lise Tarnow
professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Thomas R Mandrup-Poulsen, MD, DMSc
Role: PRINCIPAL_INVESTIGATOR
Steno Diabetes Center Copenhagen
Marc Donath
Role: STUDY_DIRECTOR
Universtity of Zürich
Flemming Pociot, DMSc
Role: STUDY_DIRECTOR
Steno Diabetes Center Copenhagen
Charles Dinarello
Role: STUDY_DIRECTOR
University of Colorado Health Science Center
Edwin Gale, Professor
Role: STUDY_CHAIR
Bristol University, UK
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Aalborg Hospital
Aalborg, , Denmark
Aarhus Universitetshospital
Aarhus, , Denmark
Bispebjerg Universitetshospital
Copenhagen, , Denmark
Steno Diabetes Center
Gentofte Municipality, , Denmark
Nordsjællands Hospital, Hillerød
Hillerød, , Denmark
Ulm University, Dept. of Internal Medicine
Ulm, Donau, Germany
Leibniz Center for Diabetes research, Heinrich-Heine University
Düsseldorf, , Germany
University of Frankfurt am Main
Frankfurt am Main, , Germany
Institut für Diabetesforschung, Munich University of Technology
Munich, , Germany
University Campus Bio-Medico
Rome, , Italy
Leiden University Medical Center
Leiden, , Netherlands
Medical University of Bialystok
Bialystok, , Poland
Hospital de Cruces, Diabetes Research Group
Barakaldo, Bizkaia, Spain
Hospital Unversitario Insular de Gran Canaria
Las Palmas, Gran Canaria, Spain
Hospital Santa Creu i Sant Pau
Barcelona, , Spain
Hospital Arnua de Vilanova
Lleida, , Spain
University Hospital Zürich
Zurich, , Switzerland
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Pickersgill LM, Mandrup-Poulsen TR. The anti-interleukin-1 in type 1 diabetes action trial--background and rationale. Diabetes Metab Res Rev. 2009 May;25(4):321-4. doi: 10.1002/dmrr.960.
Moran A, Bundy B, Becker DJ, DiMeglio LA, Gitelman SE, Goland R, Greenbaum CJ, Herold KC, Marks JB, Raskin P, Sanda S, Schatz D, Wherrett DK, Wilson DM, Krischer JP, Skyler JS; Type 1 Diabetes TrialNet Canakinumab Study Group; Pickersgill L, de Koning E, Ziegler AG, Boehm B, Badenhoop K, Schloot N, Bak JF, Pozzilli P, Mauricio D, Donath MY, Castano L, Wagner A, Lervang HH, Perrild H, Mandrup-Poulsen T; AIDA Study Group. Interleukin-1 antagonism in type 1 diabetes of recent onset: two multicentre, randomised, double-blind, placebo-controlled trials. Lancet. 2013 Jun 1;381(9881):1905-15. doi: 10.1016/S0140-6736(13)60023-9. Epub 2013 Apr 5.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
EudraCT 2007-007146-34
Identifier Type: -
Identifier Source: secondary_id
Danish EthicalH-D-2008-060
Identifier Type: -
Identifier Source: secondary_id
Danish Datatilsyn2007-41-1652
Identifier Type: -
Identifier Source: secondary_id
JDRF file no. 17-2007-1804
Identifier Type: -
Identifier Source: secondary_id
2007-007146-34
Identifier Type: -
Identifier Source: org_study_id